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The cell wall glucans of yeasts and fungi consist of a linear backbone of -1,3-linked 
glucosylunits with -1,6-linked side chains (1, 2). Although a lot is already known about the 
mechanism of action of -1,3/1,6-glucans on the innate immune system (3, 4), there is still a lot 
to be learned about their effects on the adaptive immune system in mammals. We aimed to 
determine if oral supplementation could modulate a systemic immune response. The latter was 
examined in pigs using a model antigen, but also in dogs analyzing the response against a 
parenteral vaccine. In three experiments using newly weaned pigs, Macrogard, a β-1,3/1,6-glucan 
from Saccharomyces cerevisiae, was administered in the feed during three different time periods 
(one, two and three weeks) and the adjuvant effect of this β-glucan was determined on a systemic 
immunisation with thyroglobulin. A first immunisation occurred during β-glucan 
supplementation, while the second one occurred after ceasing the administration. Macrogard 
exerted significantly higher thyroglobulin-specific primary immunoglobulin (Ig) M and 
secondary IgA antibody responses in serum. However, Macrogard suppressed the thyroglobulin-
specific proliferation of peripheral blood mononuclear cells. A higher dose of Macrogard 
significantly increased thyroglobulin-specific IgM but not IgA responses, and the animals itself 
showed hyperaemia. Suppression of the T-lymphocyte proliferation might account for the 
absence of the switch from IgM to IgA. Weight gain and feed conversion were also determined, 
without significant differences between groups. 
In another study, also dogs were orally given Macrogard in tablets, daily for four weeks. At the 
end of this period, the total serum IgA level decreased significantly in the group treated with the 
glucan compared to that in the control group as well as compared to the concentrations before 
supplementation. In contrast, the total serum IgM level rose significantly, whereas no effect on 
the IgG level occurred. Similar changes were seen in Bordetella-specific IgA and IgM titres 
following vaccination during the supplementation period. The IgA concentration also became 
significantly lower in the saliva and tears of the glucan group than in the placebo group. The 
effects disappeared one week after the cessation of the supplementation. There seems to be a 
temporary decrease in the switch from IgM to IgA due to oral Macrogard supplementation in 
dogs probably by its suppression of T-lymphocyte proliferation as seen in pigs. 
In conclusion, oral β-glucans are able to modulate the humoral as well as the cellular immunity 
against a systemically administered antigen. 
